Dec 09, 2021 / 09:30PM GMT
Operator
Hello and welcome to the Angion data call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to David Miller. Please go ahead.
David Miller - Angion Biomedica Corp. - IR
Thank you, operator.
Good afternoon, and thank you for joining us on our conference call to discuss the results of our Phase two trial of ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass, who are at risk for developing acute kidney injury, otherwise known as CSA-AKI.
On the call with me today is Dr. Jay Venkatesan, Angion's President and CEO. After the closing bell, we issued a press release with topline data from this Phase 2 study. The release is accessible on the investors section of our website at www.angion.com. A recording of this call will be available in the investors section of our website under events and presentations shortly after the call concludes.
As a reminder, before we begin, the
ANG-3777 Phase 2 CSA-AKI Results Call Transcript
Dec 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers